ABSTRACT:The in vitro metabolism of temsirolimus, (rapamycin-42-[2,2-bis-(hydroxymethyl)]-propionate), an antineoplastic agent, was studied using human liver microsomes as well as recombinant human cytochrome P450s, namely CYP3A4, 1A2, 2A6, 2C8, 2C9, 2C19, and 2E1. Fifteen metabolites were detected by liquid chromatography (LC)-tandem mass spectrometry (MS/MS or MS/MS/MS). CYP3A4 was identified as the main enzyme responsible for the metabolism of the compound. Incubation of temsirolimus with recombinant CYP3A4 produced most of the metabolites detected from incubation with human liver microsomes, which was used for large-scale preparation of the metabolites. By silica gel chromatography followed by semipreparative reverse-phase high-performance liquid chromatography, individual metabolites were separated and purified for structural elucidation and bioactivity studies. The minor metabolites (peaks 1-7) were identified as hydroxylated or desmethylated macrolide ring-opened temsirolimus derivatives by both positive and negative mass spectrometry (MS) and MS/MS spectroscopic methods. Because these compounds were unstable and only present in trace amounts, no further investigations were conducted. Six major metabolites were identified as 36-hydroxyl temsirolimus (M8), 35-hydroxyl temsirolimus (M9), 11-hydroxyl temsirolimus with an opened hemiketal ring (M10 and M11), Noxide temsirolimus (M12), and 32-O-desmethyl temsirolimus (M13) using combined LC-MS, MS/MS, MS/MS/MS, and NMR techniques. Compared with the parent compound, these metabolites showed dramatically decreased activity against LNCaP cellular proliferation.Temsirolimus (sirolimus-42-[2,2-bis-(hydroxymethyl)]-propionate) is an ester analog of rapamycin (Fig. 1), a natural macrolide antibiotic with antifungal, antitumor, and immunosuppressive activities (Sehgal et al., 1994). Temsirolimus has demonstrated significant inhibition of tumor growth both in vitro and in vivo. It binds to the cytoplasmic protein FKBP, forming a complex that antagonizes the mammalian target of rapamycin (mTOR) signaling pathway (Peralba et al., 2003), which consequently inhibits many of the downstream processes affected by mTOR kinase activity, including transcriptional and translational control of important cell cycle regulators, resulting in cell cycle arrest (Sehgal 1995). Temsirolimus is currently in phase III clinical development for the treatment of renal cancer.Although CYP3A4 had been identified as the major enzyme involved in the formation of the main metabolite of rapamycin, 41-Odesmethyl rapamycin (Christiants et al., 1992;Sattler et al., 1992; Wang et al., 1994), little additional information about rapamycin metabolism has been reported because of the complexity of the metabolic profile and the instability of the metabolites. Thus, the objective of this study was to identify the human P450 enzymes involved in temsirolimus metabolism, isolate and characterize the major metabolites, and evaluate their antitumor activities.
Materials and MethodsChemicals and Reagents. Temsiro...